Pharmaceutical and Life Sciences publications

Generating cash from Irish R&D activities

  

Pharma 2020: Marketing the future - Which path will you take?

  

Pharma 2020: Virtual R&D – Which path will you take?

Publications

Generating cash from Irish R&D activities

November 2009

Articles

Marketing: the future with John Kelly.
The latest Pharma 2020 report, which predicts marketing trends in the pharmaceutical sector, foresees a situation whereby health authorities and insurers dictate prices.

This article was first published in Business and Finance 2009 Life Science Review (June 2009)

June 2009

Press release

March 2009 - Smaller, refocused salesforce will enable pharma companies to create greater value for patients

March 2009 - Pharma CEOs more confident than leaders of other industries		  


Biotech: Listing big pharma’s prospects with biologics
With dwindling cash reserves, a squeezed credit market and a poor IPO environment, the challenges facing the biotechnology sector in 2009 are significant. However, the future looks bright with therapeutic and diagnostic biologics recently reported the fastest growing subsectors within the life sciences industry. They also played a key role in helping drive venture capital investment in the overall human biotechnology sector in 2008. In this report we focus on how biologics is acting as a catalyst for drug innovation and development and in effect, fundamentally changing the pharmaceutical sector landscape.

May 2009

Leveraging IT risk management to boost competitive advantage
The pharma and life sciences sector faces unprecedented compliance challenges and the close regulatory scrutiny of the industry is likely to only increase. A proactive and risk-based technology governance, risk and compliance approach will allow companies to better manage the cost of compliance, to streamline compliance and business processes through increased automation. and to fuel innovation objectives. Companies that take action first will not only have a greater chance of survival, but they also stand to potentially gain a significant competitive advantage.

May 2009

Pharma 2020: Challenging business models - Which path will you take?
The 4th report in the series published in June 2009 explores why traditional integrated business models which involve doing everything from R&D through to commercialisation, may not be the best option for Big Pharma companies in 2020. We believe that if companies are to prosper, more creative and collaborative business models are required. We review a number of alternative business models in the context of the future challenges facing the sector. We also look at some key self-review questions companies should consider before transitioning to a new model.

March 2009

Investing in China’s pharmaceutical industry: 2nd edition
China’s pharmaceutical market conditions continue to present significant investment opportunities. It now ranks among the top five worldwide drug markets in terms of overall size. In this, our second in-depth review of China’s changing pharmaceutical sector landscape since 2006, we explore and expand on the key issues and challenges facing companies either operating in or looking to invest in this marketplace.

March 2009

Pharma 2020: Marketing the future - Which path will you take?
The 3rd paper in the series, published in February 2009 discusses the need for companies to change their approach to marketing and sales to sustain future growth and performance. Among the dynamics reshaping the sector are the growing power of healthcare payers, providers and patients. Companies are no longer being rewarded for incremental innovation, me-too products and selling the most pills. They need to add value to patients and offer a package of products and health services for which the market is willing to pay a premium. Companies must develop marketing and sales functions fit for this changed marketplace.

February 2009

Global CEO Survey: Pharmaceutical sector summary
A financial crisis of historic magnitude was unfolding as we set out to reflect the views of over 1,124 CEOs around the world, in this our 12th annual CEO survey. CEOs are operating in very difficult conditions, with little margin for error. Pharmaceutical sector CEOs regard new product development as the key opportunity to achieve growth over the next 12 months. We also look at the key focus areas this group believe are key to achieving success over the longer term horizon.

January 2009

The changing dynamics of pharma outsourcing in Asia: Are you readjusting your sights?
In this report, we explore outsourcing in Asia as a potential response to the topical value chain productivity and cost reduction challenges. Outsourcing in Asia also leverages opportunities presented by the region’s high-growth markets and the growth in Asian pharmaceutical expertise. We discuss the key considerations for companies facing outsourcing and expansion decisions involving Asia. We also rank individual territories within the region against cost, risk and potential market opportunity criteria with a focus identifying hot spot investment locations.

September 2008

Pharma 2020: Virtual R&D – Which path will you take?
Our 2nd 2020 report explores opportunities in the area of R&D. To remain at the forefront of medical research, the industry must become more innovative in this area, reducing the time and money spent developing new therapies. We also expect new technologies to enable the adoption of ‘virtual R&D’, replacing much of the research currently performed in a lab. The sector needs to make a seismic shift from its current approach to R&D in response to the changing needs of society, essentially to operate in collaboration with researchers, governments, healthcare payers and providers in a more connected world.

June 2008

IFRS issues and solutions for the Pharmaceutical and Life Sciences industries: Vol I & II updates
This report updates the 2004 and 2005 editions of “IFRS issues and solutions for the Pharmaceutical industry”. The objective of this update is to provide greater clarity on the IFRS accounting treatment definition and interpretation for a number of industry-specific commercial issues and transactions emerging following implementation of the standards in 2005.

April 2008

IFRS issues and solutions for the Pharmaceutical and Life Sciences industries: Vol III
Partnering with another company is often the answer to long-term financing problems faced by life science and biotechnology companies or by pharmaceutical companies to the loss of patent protection and the need to adjust to the new ways of performing research. This paper discusses how both parties involved in partnerships should account for such agreements, written primarily from a revenue recognition standpoint. The publication represents a first step in trying to establish a common platform or framework for evaluating licensing and development agreements.

February 2008

US GAAP issues and solutions for the Pharmaceutical and Life Sciences industries
Accounting under US GAAP continues to evolve. With a growing demand for greater transparency and heightened regulatory scrutiny, the need to ensure correct accounting treatment for transactions has never been greater. At the same time convergence with IFRS is becoming a reality. Many non-US companies have already transitioned to IFRS and the SEC may provide US companies with a similar opportunity to transition. In this report, we examine the industry-specific accounting issues faced by the companies in the sector and our opinion on the most pertinent accounting treatment under US GAAP.

December 2007

Pharma 2020: The vision - Which path will you take?
By 2020, the context in which the industry operates will be very different from that which prevails today. This is the 1st publication in our Pharma 2020 series, published in June 2007. The report highlights a number of issues likely to have a major bearing on the industry over the next 13 years to 2020. We also discuss the changes we believe will best help companies realise the potential the future holds and will enhance the value they provide to shareholders and society alike.

May 2007